SCHEMBL21541014

SCHEMBL21541014

FC(F)(F)c1nc(Cl)cc(N2CCOCC2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.60
CYP2D6 P10635 1/20 0.60
MAPT P10636 1/20 0.60
KMT2A Q03164 3/20 0.56
NPSR1 Q6W5P4 1/20 0.48
RAF1 P04049 1/20 0.46
BRAF P15056 1/20 0.46
PIK3CA P42336 4/20 0.44
MTOR P42345 3/20 0.44
PIK3R1 P27986 2/20 0.44
HTT P42858 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
PIK3CB P42338 2/20 0.41
PIK3CD O00329 1/20 0.41
PIK3C2B O00750 1/20 0.41
AKR1C3 P42330 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2560108 0.83 MAPT (0.58) CYP1A2CYP2D6MAPTKMT2ANPSR1
SCHEMBL16094875 0.82 CYP1A2 (0.57) CYP1A2CYP2D6MAPTKMT2ANPSR1
SCHEMBL13989245 0.79 MAPT (0.66) CYP1A2CYP2D6MAPTKMT2ANPSR1
SCHEMBL856815 0.78 MAPT (0.70) CYP1A2CYP2D6MAPTKMT2ANPSR1
SCHEMBL29762330 0.78 MAPT (0.70) CYP1A2CYP2D6MAPTKMT2ANPSR1
SCHEMBL31616206 0.77 SYK (0.39) CYP1A2CYP2D6MAPTKMT2ARAF1
SCHEMBL855348 0.77 MAPT (0.68) CYP1A2CYP2D6MAPTKMT2ANPSR1
SCHEMBL21520311 0.76 CYP17A1 (0.41) CYP1A2CYP2D6MAPTRAF1BRAF
SCHEMBL1028538 0.76 CYP1A2 (1.00) CYP1A2CYP2D6MAPTKMT2ARAF1
SCHEMBL30353341 0.76 CYP1A2 (0.66) CYP1A2CYP2D6MAPTKMT2ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654834-B2 Non-systemic TGR5 agonists Venenum Biodesign, LLC (US) 2020-05-19 US disclosed
US-20190330191-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS Venenum Biodesign, LLC (US) 2019-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190330191-A1 NOVEL NON-SYSTEMIC TGR5 AGONISTS GPR119, FFAR1, FFAR3 CYP1A2 1439/4885CYP2D6 1941/4885MAPT 3811/4885
US-10654834-B2 Non-systemic TGR5 agonists GPR119, SSTR5, FFAR3 CYP1A2 1241/4885CYP2D6 1857/4885MAPT 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.